Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set

Leuk Lymphoma. 2021 May;62(5):1243-1246. doi: 10.1080/10428194.2020.1864356. Epub 2021 Jan 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boron Compounds
  • Dexamethasone / therapeutic use
  • Glycine / analogs & derivatives
  • Humans
  • Lenalidomide / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics
  • Neoplasm Recurrence, Local / drug therapy
  • Proteasome Inhibitors* / therapeutic use

Substances

  • Boron Compounds
  • Proteasome Inhibitors
  • ixazomib
  • Dexamethasone
  • Lenalidomide
  • Glycine